Esteve Pharmaceuticals S.A. v. Controller Of Patents And Designs

Every pharmaceutical company dreams of finding the next breakthrough molecule. But what happens when the breakthrough isn't a new molecule at all, but rather a new way of crystallizing two existing ones together? For Esteve Pharmaceuticals S.A., this question became the center of a high-stakes legal fight against India's patent authorities, a fight that cuts to the heart of what truly counts as invention in the pharmaceutical world.

Esteve Pharmaceuticals S.A., a Spanish pharmaceutical company, filed Indian Patent Application No. 1435/DELNP/2012 seeking protection for a co-crystal formulation combining Tramadol, a widely used pain reliever, and Celecoxib, a well-known anti-inflammatory drug. A co-crystal is a unique crystalline structure where two distinct active pharmaceutical ingredients are arranged together in a single crystal lattice, potentially offering improved properties over simply mixing the two drugs. However, the Controller of Patents and Designs in India rejected the application, holding that the invention lacked novelty and an inventive step. The rejection specifically cited Section 3(d) and Section 3(e) of the Indian Patents Act, provisions designed to prevent companies from securing fresh patents on known substances or simple combinations of existing drugs.

Esteve Pharmaceuticals argued that its co-crystal formulation represented a genuine technical advancement, not merely a new form of known substances thrown together. From the company's perspective, the precise crystalline arrangement of Tramadol and Celecoxib produced a novel entity with distinct pharmacological properties that neither drug could achieve alone. On the other side, the Controller of Patents and Designs took a hardline stance rooted in India's stringent patentability standards. Section 3(d) famously blocks patents on new forms of known substances unless the applicant can demonstrate significantly enhanced therapeutic efficacy, a high bar designed to stop the practice of evergreening, where companies extend patent monopolies by making minor tweaks to existing drugs. Section 3(e) further restricts patents on mere combinations of known substances. Together, these provisions created a formidable legal wall that Esteve's co-crystal had to climb over.

As of the hearing on 11 April 2023, the matter remained pending before the court. The case underscores the ongoing judicial scrutiny applied to pharmaceutical patent applications in India, particularly those involving co-crystals and polymorphs. While the final ruling awaits, the dispute itself illustrates how India's patent framework treats structural innovations involving known drugs with deep skepticism, demanding clear evidence that the new form delivers something the original substances cannot.

For founders and IP professionals in the pharmaceutical and life sciences space, this case is a powerful reminder that innovation in drug formulation is not evaluated the same way everywhere. In jurisdictions with strict anti-evergreening laws like India, simply creating a new physical form or combination of known active ingredients is rarely enough to secure a patent. To succeed, applicants must build a robust evidentiary record demonstrating significantly enhanced efficacy or a genuinely unexpected technical effect. Before investing heavily in formulation-based IP, startups should conduct jurisdiction-specific patentability assessments and